(Q39155735)

9 September 2017

title

Rucaparib: First Global Approval (English)

1 reference

9 September 2017

Yahiya Y Syed

1

1 reference

9 September 2017

publication date

1 March 2017

1 reference

9 September 2017

1 reference

9 September 2017

volume

77

1 reference

9 September 2017

issue

5

1 reference

9 September 2017

page(s)

585-592

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-017-0716-2

9 September 2017

exact match

0 references

cites work

Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0716-2

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0716-2

Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0716-2

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0716-2

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0716-2

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0716-2

Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0716-2

Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0716-2

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0716-2

The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0716-2

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0716-2

Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0716-2

NF-κB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0716-2

An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0716-2

Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0716-2

The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0716-2

Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0716-2

Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0716-2

Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0716-2

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0716-2

INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0716-2

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0716-2

10.1007/S40265-017-0716-2

21 January 2018

Identifiers

DOI

1 reference

9 September 2017

1 reference